Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Despite Headwinds US IPOs Show Few Signs Of Slowing In Q3

This article was originally published in Scrip

Executive Summary

Fifteen drug development firms raised $1.4bn via initial public offerings in the US during the third quarter, which is equal to the quarterly average during the first half of the year and shows that despite recent biotechnology stock headwinds IPOs have not slowed – at least, not yet.

Advertisement

Related Content

IPO Update: Novan, AC Immune End Summer Slowdown As Market Improves
venBio's $315m Pharma-Backed Fund Seeks Broad Range Of Investments

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register